Description: 

This webinar re-playing the popular session from the Obesity Medicine Conference 2021 provides a brief overview of FDA-approved anti-obesity medications (AOM’s). The webinar includes a series of case presentations exploring obesity medication options in specific patient scenarios. Dr. Primack will be answering questions throughout the presentation as well as having 10 minutes of Q&A at the end of the presentation.

Accreditation: 

The Obesity Medicine Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Medicine Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME/CE Expiration Date: 8/28/2021* 

*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.

Description: 

The Semaglutide Treatment Effect in People with Obesity (STEP) Trials have been described as a game changer for obesity treatment. In this webinar Dr. Kushner will review the efficacy and safety outcomes of the four STEP trials and their importance for obesity patient care.

Accreditation: 

The Obesity Medicine Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Medicine Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME/CE Expiration Date: 8/14/2021* 

*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.

Description: 

The global COVID-19 pandemic has turned our patient’s lives and routines upside down. Physical activity has been a struggle for many of our patients and can be one of the most difficult behaviors to establish for many individuals, whether they have obesity or not. Due to the pandemic, long time and brand-new gym aficionados were shut out from gyms and group fitness classes. Routines, which are key triggers for engaging in health behaviors, were thrown out the window. Fear set in, especially for our patients, all of whom are high risk for serious adverse outcomes from the coronavirus.

In this webinar, we will review the impact of physical activity on immune health in patients with obesity and metabolic disease. We will review the data on how the pandemic has affected physical activity levels. We will discuss how we can use technology and virtual fitness options with our patients, and how we can use telemedicine and behavioral strategies to help our patients overcome barriers to being active, including the new barriers imposed on us by the current pandemic. 

Accreditation: 

The Obesity Medicine Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Medicine Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME/CE Expiration Date: 7/23/2021* 

*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.

CME/CE Expiration Date: 4/25/2024* *The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.

Description: 

With limited options and cost limitations for prescribing anti-obesity medications, experienced obesity medicine specialists recognize the importance of off-label use of medication for obesity treatment. This session will briefly review medications that are known to aid in weight loss but lack FDA approval for use in obesity treatment. The session will also include discussion of long-term use of medications that are only approved by the FDA for short-term use. The program will include an interactive discussion of a number of patient scenarios where alternative medications can be considered for obesity treatment.

Accreditation:       

The Obesity Medicine Association (OMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

The Obesity Medicine Association designates this internet enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

CME/CE Expiration Date: 4/25/2024* 

*The expiration date listed above is the last day CME/CE credit can be claimed for these specific presentations.

Description: 

Obesity prevalence is at worldwide epidemic levels, and behind cigarette smoking, obesity is the second leading cause of preventable deaths. Interventions directed toward improving nutrition, increasing physical activity, and changing eating behaviors can be effective treatments for obesity, but long -term benefits are often countered by neuro-hormonally activated homeostatic mechanisms that eventually lead to weight regain. Anti-obesity pharmacologic agents are often effective in combating the internal drives that increase appetite and contribute to obesity as well as those associated with weight regain. Despite the prevalence and deadly consequences of obesity, there are currently only four FDA approved anti-obesity medications for long -term use and four older sympathomimetic agents approved only three month’s treatment duration. Pharmacologic options for obesity treatment are further limited by other factors that include medication expense and lack of insurance coverage, concurrent medical conditions, drug interactions, adverse drug effects, and individual lack of therapeutic response in some individuals.  

Fortunately, there are options that are not FDA approved (off-label) that are generally safe and efficacious for obesity treatment backed by clinical experience and medical literature. This educational series will focus on safe and efficacious obesity treatment in challenging patients when FDA approved therapeutic agents are not an option. 

With disease management, the weight-gain potential of medications is often not considered when choosing pharmacotherapy options. Many commonly used medications associated with weight gain have alternatives with weight neutral or weight losing effects.  Shifting medication choices from weight positive to weight neutral or negative choices can be an effective means of facilitating weight loss. 

Accreditation: 

The Obesity Medicine Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Medicine Association designates this enduring material for a maximum of 3 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME/CE Expiration Date: 4/25/2024* *The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.

Description: 

Accreditation:       

The Obesity Medicine Association (OMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

The Obesity Medicine Association designates this internet enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

CME/CE Expiration Date: 4/25/2024* *The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.

Description: 

Treatment of people with unhealthy weight has typically focused on those with obesity or in those with BMI ≥ 27 with existing comorbidities; however, evidence indicates that the negative effects of excess weight on morbidity and mortality begin at lower BMI categories. Properly identifying at-risk patients who have pre-obesity and initiating treatment earlier may interrupt the progression towards further weight gain, obesity, and prevent or delay comorbidities. This engaging and interactive session will underscore the risks associated with pre-obesity, highlight best practices for screening and taking a weight history, and review practical treatment strategies to halt progression of the disease.  

Accreditation:       

The Obesity Medicine Association (OMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

The Obesity Medicine Association designates this internet enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

CME/CE Expiration Date: 4/25/2024* *The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.

Description: 

This session provides a brief overview of FDA-approved anti-obesity medications (AOM’s). The session includes a series of case presentations exploring medication options in specific patient scenarios.

Accreditation:       

The Obesity Medicine Association (OMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

The Obesity Medicine Association designates this internet enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

CME/CE Expiration Date: 4/25/2024* *The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.

Description: 

Binge eating disorder (BED) is present in 30% of adults who seek obesity treatment. Of children who seek treatment for obesity, 9% have over-eating episodes. While BED is a common problem among patients seen in an obesity medicine practice, often it is not screened for and may be overlooked. Some studies indicate a greater chance of relapse for patients with obesity have lost weight and have BED. Recognizing and treating BED is a crucial part of providing care for our patients with obesity. This presentation will review the epidemiology, signs and symptoms, diagnosis, and treatment of patients with BED utilizing case presentations to illustrate the best treatment strategies to optimize outcomes in this patient population.

Accreditation:       

The Obesity Medicine Association (OMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

The Obesity Medicine Association designates this internet enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

CME/CE Expiration Date: 4/25/2024* *The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.

Description: 

This presentation will review the barriers and challenges in receiving obesity treatment as perceived by people with obesity, health care providers and employers, and provide solutions for how these misalignments are easily rectifiable in the primary care setting.  During this session receive customized training in obesity management tailored for primary care providers. Additionally, participants will develop individualized dietary treatment recommendations for patients with obesity. 

This presentation will review the barriers to effective medical care for persons with obesity as identified in the ACTION (Awareness, Care, and Treatment In Obesity Management) study.

Accreditation:       

The Obesity Medicine Association (OMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

The Obesity Medicine Association designates this internet enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should only claim the credit commensurate with the extent of their participation in the activity.